The diagnostics, treatment and five-year survival rates for bladder cancer are largely unchanged since the 1990s. Research into cancer genomics, risk factors and immune therapies could hold the key to progress against this malignant disease.
Layers of risk
Most cases of bladder cancer occur in the cells of the bladder’s innermost lining, the urothelium. In most patients, the cancer has not spread far. These ‘non-muscle-invasive’ tumours are easier to treat and much less lethal than tumours that have grown into the muscle wall or beyond.
Bladder-cancer diagnoses
Most cases of bladder cancer are the urothelial type. The less-common types are: squamous cell carcinoma, adenocarcinoma, small-cell carcinoma, and sarcoma.
No comfort for old men
Men are about three to four times more likely than women to get bladder cancer, but women are typically diagnosed with more-advanced cancer and have a worse prognosis. Worldwide, bladder cancer is the ninth-most-common cancer and the thirteenth deadliest. But in more-developed countries (below), it poses a bigger threat than many other cancers because fewer new treatment and prevention options have been developed.
Survival and recurrence
Survival unchanged
Unlike many other cancers, there has been no improvement in survival rates for bladder cancer for three decades.
Recurrence
After surgery, people with bladder cancer should have regular cystoscopies (typically every three months for the first year or two, and then every six months) to see if the cancer returns, as well as imaging and urine tests.
Sources:
1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012; available at http://go.nature.com/2znpnyy
2. Ploussard, G. et al. Eur. Urol. 66, 120–137 (2014).
3. NIH Surveillance, Epidemiology and End Results Program; available at http://go.nature.com/2yk45st
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Characteristics and clinical significance of histological variants of bladder cancer
The evolving genomic landscape of urothelial carcinoma
A community map of cancer immunity
Related external links
Rights and permissions
About this article
Cite this article
Berdik, C. Unlocking bladder cancer. Nature 551, S34–S35 (2017). https://doi.org/10.1038/551S34a
Published:
Issue Date:
DOI: https://doi.org/10.1038/551S34a
This article is cited by
-
Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer
BMC Cancer (2024)
-
Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer
Scientific Reports (2024)
-
Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer
BMC Urology (2023)
-
SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein
Cancer Cell International (2023)
-
Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses
Scientific Reports (2023)